Business Context and Reporting Period
This Form 8-K Current Report from Medicus Pharma Ltd. (MDCX) covers events occurring on June 3, 2025, and June 4, 2025. The Company, an emerging growth company incorporated in Ontario, is based in Conshohocken, Pennsylvania. The filing primarily addresses a change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the current period. However, it references the prior year's financial condition:
- Going Concern Status: The prior auditor, EisnerAmper LLP, issued a report for the year ended December 31, 2024, containing a separate paragraph raising substantial doubt about the Company's ability to continue as a going concern due to negative cash flows from operating activities and incurred operating losses.
- Internal Controls: Material weaknesses in internal control over financial reporting were identified for the fiscal year ended December 31, 2024, and the quarter ended March 31, 2025.
Material Changes Versus Prior Period
The primary material change reported is the dismissal of EisnerAmper LLP as the independent registered public accounting firm, effective June 3, 2025. This decision was recommended by the Audit Committee and approved by the Board of Directors. Concurrently, the Company engaged KPMG LLP as its new independent registered public accounting firm on June 4, 2025, to audit financial statements for the year ending December 31, 2025.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Risks:
- Accounting Disagreements: The Company reported no disagreements with EisnerAmper regarding accounting principles, practices, or audit scope during the relevant periods.
- Material Weaknesses: The filing reiterates previously disclosed material weaknesses related to:
- Lack of precision in reviewing materials used to record transactions under U.S. GAAP.
- Lack of formalized or documented policies for the IT system environment, including security, cybersecurity, patches, and user access.
- Impact on Financials: Management stated that these material weaknesses did not result in the restatement of previously reported financial statements and did not affect the accuracy of financial statements for periods ended December 31, 2024, and March 31, 2025.
- Successor Auditor: No consultations occurred with KPMG regarding accounting principles or audit opinions prior to their engagement.
Important Facts for Investor Verification
- Verify the Company's current liquidity position and capital raise plans given the "substantial doubt" regarding going concern status noted in the 2024 audit.
- Review the specific remediation plans for the identified material weaknesses in internal controls over financial reporting and IT security.
- Confirm the timeline for KPMG's initial audit and any potential delays in future financial reporting.
- Examine the letter from EisnerAmper (Exhibit 16.1) to ensure there are no undisclosed disagreements or reportable events.